scFv(GPC3)-41BB-CD3zeta CAR-T Lentivirus

scFv(GPC3)-41BB-CD3zeta CAR-T lentivirus is a gene delivery vector designed to robustly genetically modify primary human T lymphocytes to express a second-generation chimeric antigen receptor (CAR) specifically targeting Glypican-3. One of the main advantages of using lentiviral vector systems is their ability to achieve stable, long-term genome integration, ensuring that the CAR transgene is delivered to all progeny cells during T cell expansion. This is crucial for achieving sustained therapeutic effects in adoptive cell therapy. The vector exhibits high transduction efficiency even in quiescent or slowly dividing primary T cells, a characteristic that significantly outperforms traditional retroviral vectors. Structurally, the second-generation CAR encoded by this virus contains a high-affinity single-stranded variable region fragment (scFv) derived from an anti-GPC3 antibody, optimized for precise antigen recognition. It is linked to a 4-1BB (CD137) co-stimulatory domain, which plays a key role in enhancing the metabolic adaptability and long-term survival of T cells in the host.

In terms of applications, scFv(GPC3)-41BB-CD3zeta CAR-T lentivirus is an indispensable tool in oncology and immunotherapy research, particularly suitable for treating hepatocellular carcinoma (HCC) and other GPC3-positive malignancies such as yolk sac tumors, squamous cell lung cancer, and embryonal carcinoma. Because GPC3 is overexpressed on the surface of these cancer cells but almost not expressed in healthy adult tissues, it is an ideal candidate target for CAR-T therapy with extremely low off-target toxicity. Researchers have used these lentiviral particles to construct standardized batches of CAR-T cells for various functional assays. In vitro, the system quantifies the cytotoxicity of modified T cells and detects the secretion of pro-inflammatory cytokines such as interferon-γ (IFN-γ) and interleukin-2 (IL-2) through co-culture experiments with GPC3-expressing target cells. Furthermore, by injecting the resulting CAR-T cells into tumor-bearing immunodeficient mice, scientists can study the cell biodistribution, their ability to infiltrate dense solid tumor stroma, and their efficacy in reducing tumor volume over time.